Gainesville, Fla. (May 2, 2016) – Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic materials for extremities, knee, hip and spine, announced today that in honor of the company’s 20th anniversary of its Nasdaq listing, Exactech founders Bill Petty, MD, Betty Petty and Gary Miller, PhD, will ring the Nasdaq Closing Bell on Tuesday, May 3. The ceremony will take place from 3:45 – 4:00 p.m. ET at Nasdaq MarketSite in Times Square, New York.
“We appreciate this opportunity to commemorate 20 years on Nasdaq and to recognize the positive impact our company’s growth has had on employees, surgeon customers and the patients whose lives are improved by our products,” said Exactech Chief Executive Officer David Petty. “Exactech has always taken a unique approach to the business of orthopaedics. Our purpose of improving outcomes for patients and our unwavering focus on meeting our surgeons’ needs have also yielded solid financial returns for our shareholders. We ring the bell in honor of our past and with eager anticipation of our future.”
Founded in 1985 by an orthopaedic surgeon, his wife and a biomedical engineer, Exactech’s first product was a cemented primary hip system, followed quickly by additional hip joint products. Building on its success in total hip replacement, the company established a relationship with Albert Burstein, PhD, and the Hospital for Special Surgery in 1992 to develop its first knee implant, the Optetrak® knee system. To raise capital to support full commercialization of Optetrak, Exactech went public with an IPO on Nasdaq in 1996 at a post-2003 2-for-1 stock split price of $4.00. The company’s IPO market cap was approximately $39 million. At the end of 1996, the company reported $13.8 million in sales and net income of $1.5 million, and has been profitable every year since.
Exactech entered the extremities market in 2005 with the launch of the Equinoxe® platform shoulder system. This product quickly gained surgeon acceptance and has been a market leader for more than 10 years. Today, Equinoxe is one of the fastest-growing shoulder systems on the market, with more than 60,000 patients treated and 73 peer-reviewed studies published.
With a focus on international expansion that was initiated in 2010, the company now operates in more than 35 countries in Europe, Latin America, Asia and the Pacific, including direct operations in nine markets outside the United States. In 2014, Exactech acquired an advanced, computer-assisted surgical technology company and introduced ExactechGPS® Guided Personalized Surgery, which has the potential to change the way total joint replacement surgery is performed.
Over the past 20 years, Exactech also developed biologic materials, invested heavily in internal manufacturing, introduced the first preformed antibiotic spacer for hip, knee and shoulder in the United States and acquired a spine company and additional spine technology.
At year-end 2015, Exactech reported revenues of $241.8 million and net income of $14.8 million with a market cap of more than $300 million. This year, the company will bring to market three systems to address complex hip, knee and shoulder surgeries in revision arthroplasty, followed by the VantageTM total ankle in 2017. The stock closed Friday April 29th, 2016 at $22.74.
The bell-ringing ceremony will be led by the company’s founders, Executive Chairman Dr. Bill Petty, Dr. Gary Miller and Betty Petty and CEO David Petty, the company’s first employee.
A live stream of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live orhttp://www.nasdaq.com/about/marketsitetowervideo.asx
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.
This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.
Executive Vice President of Finance & Chief Financial Officer
Julie Marshall or Frank Hawkins
Vice President, Corporate & Marketing Communication